UP202-56 

UP202-56 is an adenosine analogue, which is an adenosinergic agonist.

Adenosine Receptor^[1][2]

The effects of oral administration of UP202-56, an adenosine analogue, are assessed on carrageenan-induced spinal c-Fos protein expression and peripheral oedema. Oral UP202-56 (10, 30 or 50 mg/kg) dose-dependently reduces the number of carrageenan-induced c-Fos like immunoreactivity (c-Fos-LI) neurons (r=0.931. P<0.0001), with the highest dose of UP202-56 producing 72±4% reduction of the total number of carrageenan-induced spinal c-Fos-LI neurons, and 12±3% and 33±6% of reduction of control carrageenan oedema at paw and ankle levels, respectively. UP202-56 dose-dependently reduces the spinal c-Fos protein expression in carrageenan model of inflammatory pain^[1]. UP202-56 is an adenosinergic agonist^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

595.69

C₃₃H₃₇N₇O₄

163838-04-8

O[C@H]1[C@@H](O[C@@H]([C@H]1O)C(NC2CC2)=O)N3C4=NC=NC(NCCC(C5=C6)=CN(CC7=C(C=CC(C)=C7)C)C5=CC=C6C)=C4N=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Honoré P, et al. UP 202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression. Pain. 1998 Apr;75(2-3):281-93.  [Content Brief]

  [2]. Camborde, Francois, et al. PHARMACEUTICAL COMBINATION WITH ANALGESIC ACTIVITY, CONTAINING AN ADENOSINERGIC AGONIST AND A COMPOUND SELECTED FROM OPIATES, BENZODIAZEPINES AND NMDA ANTAGONISTS. Patent Application WO/1999/029347.